Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment

Puntos clave

• Endocrine-sensitive breast cancer treatment is improved with the addition of proton-pump inhibitors.
• Palbociclib or abemaciclib combined with proton-pump inhibitors shows significant enhancement in treatment efficacy.
• The assessment utilizes a combination of signaling pathways impacted by hormonal therapy.
• These findings highlight the potential for proton-pump inhibitors to enhance cancer treatment outcomes.